Carneiro, A., Hahn, A., Ellmark, P., Enell Smith, K., Schultz, L., Ambarkhane, S., Yachnin, J., Ullenhag, G. J.

First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies

23 de January de 2025 by Carneiro, A., Hahn, A., Ellmark, P., Enell Smith, K., Schultz, L., Ambarkhane, S., Yachnin, J., Ullenhag, G. J.

Background
ATOR-1017 (evunzekibart) is a human agonistic immunoglobulin G4 antibody targeting the costimulatory receptor 4-1BB (CD137). ATOR-1017 activates T cells and natural killer cells in the tumor environment, leading to immune-mediated tumor cel…